Credit Suisse upgrades GSK, downgrades AstraZeneca
15th Sep 2022 13:49
(Sharecast News) - Credit Suisse upgraded GlaxoSmithKline on Thursday but downgraded AstraZeneca as it took a look at the pharmaceuticals sector.
Read moreAstraZeneca's biliary tract cancer treatment receives US approval
5th Sep 2022 07:08
(Sharecast News) - Drugmaker AstraZeneca said on Monday that its biliary tract cancer treatment had been granted US approval to be used as the first immunotherapy regimen for patients with the disease.
Read moreAstraZeneca's Evusheld approved in Japan for treatment, prevention of Covid-19
30th Aug 2022 13:42
(Sharecast News) - AstraZeneca said on Tuesday that its Evusheld long-acting antibody combination has been approved in Japan for the prevention and treatment of Covid-19.
Read moreClinical trials demonstrate that AstraZeneca's Farxiga reduces risk of cardiovascular death
30th Aug 2022 07:20
(Sharecast News) - Clinical trial results showed that AstraZeneca's Farxiga treatment against Type II diabetes significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction.
Read moreShoreCap stays at 'buy' for Astra Zeneca, citing prospects for earnings and sales growth, pipeline
25th Aug 2022 15:43
(Sharecast News) - Analysts at ShoreCap doubled down on their recent reinitiation of coverage on AstraZeneca with a 'buy' recommendation, citing growth and pipeline prospects.
Read moreAstraZeneca's Lynparza approved in Japan
25th Aug 2022 08:05
(Sharecast News) - AstraZeneca and MSD's Lynparza has been approved in Japan for the treatment of patients with BRCA-mutated (BRCAm), HER2-negative early breast cancer at high risk of recurrence, the companies said on Thursday.
Read moreSector movers: Defensives knocking at technical resistance's door
20th Aug 2022 17:01
(Sharecast News) - Interest rate sensitive segments of the FTSE 3500 dragged the index lower at the end of the week, as investors digested a flurry of Fed speakers overnight whose overarching message appeared to be that interest rates would remain higher for longer, although there were slight variations as to just how high.
Read moreAstraZeneca's prostate cancer drug gets US priority review
16th Aug 2022 08:07
(Sharecast News) - Pharmaceutical company AstraZeneca said its Lynparza prostate cancer treatment application had been granted priority review in the US.
Read moreAstraZeneca breast cancer drug meets primary and secondary endpoints in new trial
15th Aug 2022 07:27
(Sharecast News) - Drugmaker AstraZeneca said on Monday that positive high-level results from a new trial of its Enhertu breast cancer drug had demonstrating a "statistically significant and clinically meaningful improvement" in progression-free survival.
Read moreAstraZeneca, Daiichi's Enhurtu gets US approval to treat lung cancer
12th Aug 2022 07:04
(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu drug has been approved in the US for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer, the companies said on Friday.
Read moreAstraZeneca gets US approval for breast cancer treatment
8th Aug 2022 09:49
(Sharecast News) - AstraZeneca's breast cancer treatment candidate 'Enhertu', or trastuzumab deruxtecan, has been approved in the United States, it announced on Monday.
Read moreAstraZeneca breast cancer drug receives EU approval
4th Aug 2022 08:52
(Sharecast News) - Drugmaker AstraZeneca's Lynparza has received European Union approval for use in the adjuvant treatment of adult patients with high-risk early-stage breast cancer, including those with germline BRCA mutations.
Read moreShoreCap stays at 'buy' on AstraZeneca, sees further upgrades ahead on product pipeline
29th Jul 2022 12:45
(Sharecast News) - Analysts at ShoreCap reiterated their 'buy' recommendation for shares of drugs giant AstraZeneca, describing its second quarter top-line growth of 37% year-on-year at constant exchange rates "impressive".
Read moreAstraZeneca raises FY revenue guidance, names new chairman
29th Jul 2022 07:07
(Sharecast News) - Drugmaker AstraZeneca raised full-year revenue guidance on Friday as it provided details of its "strong" first trading half and announced that Michel Demaré would take over as the group's chairman in April 2023.
Read moreFriday preview: US inflation data, AstraZeneca in the spotlight
28th Jul 2022 12:22
(Sharecast News) - All eyes at the end of the week will be on a slew of inflation indicators due out in the US.
Read more